Mitochondrial protein may improve selective liver cancer treatment

Hepatocarcinoma is the most commonly diagnosed form of liver cancer. It is an aggressive, fast growing cancer with a 5-year survival rate of only 15%. Thomas Jefferson University researcher Gyorgy Hajnoczky, MD/Ph.D., and his team recently found that a protein in mitochondria called VDAC2, may be a key player in making liver cancer cells more susceptible to cell death than normal liver tissue…